Immuno-Oncology | Specialty

Dr. Kandalaft on an Ovarian Cancer Immunotherapy

March 5th 2013

Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

February 16th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Dr. Oh on Combination Therapy in Prostate Cancer

January 8th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

Dr. Gettinger on Lung Cancer Immunotherapies

January 8th 2013

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Novel Cancer Vaccine Fails To Significantly Improve Overall Survival in Lung Cancer

December 21st 2012

Results of a large phase III trial testing the efficacy of the investigational vaccine L-BLP25 in patients with advanced lung cancer found that the vaccine failed to show a statistically significant improvement in overall survival

A Nobel Prize in Waiting: Understanding Unexpected and Prolonged Remissions

December 19th 2012

Ipilimumab provides a striking example of the way in which some patients derive long-term benefits from therapy while others do not. The reasons for such differences should be a priority for translational research.

Dr. Gettinger on PD-1 Inhibitor BMS-936558 in NSCLC

December 11th 2012

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

Dr. Renier Brentjens on Genetically-Modified T Cells

November 21st 2012

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, explains the process by which his laboratory at MSKCC genetically modifies immune cells to fight cancer.

Vaccine Promotes Immune Response in Ovarian Cancer

November 19th 2012

Interim data from a phase II clinical study of the dendritic cell vaccine CVac in patients with epithelial ovarian cancer showed promising signs of improving PFS compared with the observational standard of care.

Five PD-1-Related Questions for Suzanne L. Topalian, MD

November 5th 2012

Suzanne L. Topalian, MD, has led clinical development of monoclonal antibodies to treat patients with melanoma and other solid tumors, including those targeting the PD-1 T cell co-receptor.

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

November 2nd 2012

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Targeting PD-1: Immune Checkpoint Strategy Finds New Spot to Arrest Cancer

October 31st 2012

Increasing evidence suggests that the ability to outsmart the body's immune response represents a hallmark of tumor development.

Dr. Rotkowitz on Ipilimumab Plus Dacarbazine for Melanoma

October 26th 2012

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Robust Sipuleucel-T Immune Activity Is Detailed in Pooled Data Analysis

October 24th 2012

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

Dr. Ribas on Combining Vemurafenib and Ipilimumab

October 9th 2012

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

New Metastatic Melanoma Therapies Create Hope for Patients, Key Role for Oncology Nurses

October 8th 2012

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma

October 3rd 2012

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Dr. Petrylak Explains How Sipuleucel-T Impacts Survival

September 7th 2012

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.